Numinus Q4 Revenue Jumps 29% to $2.3M, Gross Margin Hits 61%
NUMIF has more than doubled off its 52-week low of $0.006 on elevated volume (2.5× avg).
Summary
Numinus reported Q4 fiscal 2025 revenue of $2.3 million, up 29% sequentially, with gross margin expanding to 61.2% from 48.3%. Practitioner training revenue surged 387.6% to $1.0 million, while clinical research revenue dipped 13.2% to $1.4 million on seasonality. The company ended the quarter with only $0.5 million in cash and a $2.7 million working capital deficiency, underscoring liquidity risk. Management reiterated plans to complete the audit, file outstanding interim reports, and seek CSE listing to lift the cease trade order. The board appointed former CFO John Fong as an independent director. Separately, the April 2026 U.S. executive order on psychedelic research is viewed as a positive regulatory development, though impact depends on FDA and DEA implementation.
At the time of this announcement, NUMIF was trading at $0.04 on OTC in the Life Sciences sector, with a market capitalization of approximately $12.5M. The 52-week trading range was $0.01 to $0.06. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: TMX Newsfile.